Dr. Jan Engels

Investment Manager

Following a bachelor’s degree in biotechnology, Dr. Jan F. Engels completed a PhD in chemistry and nanotechnology in Hong Kong, where he stayed the past 10 years. During his PhD studies he co-founded a medical device start-up in the field of ophthalmology and drug delivery with the position as VP technology. Next to R&D, his focus was on technology patents and business development with successful collaborations with listed companies in US, Europe, and Japan. Next to his start-up position, Jan has a part time lecturer position, teaching Entrepreneurship. After returning to Germany, he joined High-Tech Gründerfonds as an Investment Manager Life Science.

Portfolio

Posts & mentions

Press

26. October 2023

RAYDIAX secures €3.5 million in fresh capital to develop its therapy assistance computed tomography system in the fight against cancer

RAYDIAX, a Magdeburg spin-off of the STIMULATE research campus, secures a total of €3.5 million in seed funding and grants The capital will be used to advance the development of RAYDIAX’s assistance system for image-guided, minimally invasive cancer interventions up to the pre-clinical prototype and to accelerate market development in Europe and the US Investors in the seed round include High-Tech Gründerfonds (HTGF), bmp Ventures with the IBG funds and experienced business a

Press

12. July 2023

ReCatalyst Announces Successful Closing of Oversubscribed Seed Financing Round

ReCatalyst is developing a nano-tech platform for production of next-generation of intermetallic platinum-alloy PEM fuel cell catalysts with the core mission to enable an optimized usage of platinum group metals. Slovenian Startup ReCatalyst was able to convince an outstanding international syndicate consisting of HTGF, xista science ventures and OCCIDENT, along with Slovenian investors, to invest €1.7 million. The funding will be used to enhance market readiness and accele

Press

23. March 2023

Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round

Munich, Germany, 23 March 2023 – mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors. mbiomics uses its proprietary, tailored high-resolution profiling platform and computat

Press

26. January 2023

Refined Laser Systems Raises €2.7m to Diagnose Cancer in Minutes

Refined Laser Systems has developed an innovative microscopy procedure to support pathology in diagnosing cancer within minutes and avoid revision surgeries. The investment was led by High-Tech Gründerfonds and APEX Ventures alongside Onsight Ventures, NRW.BANK, and Papst Venture Capital. The Seed funding will be used to develop an intraoperative microscope prototype that identifies tumor margins directly in the surgery room and will offer a diagnosis within minutes by a remote patho